EUVIMEDEUVIMED entdecken
Crossref

Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma

Akimasa Sanagawa iD, Tomoaki Hayakawa, Emi Nishida, Aya Yamamoto, Kyoko Ikumi, Yukari Mori, Yuji Hotta, Kazunori Kimura, Yoko Furukawa-Hibi iD, Akimichi Morita iD

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Akimasa Sanagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Hypertriglyceridemia, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Minophagen Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bexarotene is an effective oral drug for the treatment of cutaneous T‐cell lymphoma, but careful management is required due to its various side effects. In particular, hypertriglyceridemia often requires a reduction or even suspension of bexarotene therapy. The risk factors of bexarotene‐associated severe hypertriglyceridemia are not clear. Here, we conducted a post hoc analysis of the data from our previous clinical trial, which confirmed the efficacy and safety of combined bexarotene and phototherapy, to evaluate the effect of body mass index on bexarotene‐associated hypertriglyceridemia. Twenty‐five subjects were divided into two subgroups: normal and underweight (body mass index [BMI]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousHypertriglyceridemiaSkin NeoplasmsHumansBexaroteneBody Mass IndexTetrahydronaphthalenesEast Asian PeopleOverweightPhototherapyObesity

Stichwörter der Autor:innen

bexarotenecutaneous T-cell lymphomahypertriglyceridemiaobesityoverweight

Substanzen

BexaroteneTetrahydronaphthalenes

Autor:innen und Institutionen

  • Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
  • Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Akimasa Sanagawa, Yoko Furukawa-Hibi, Akimichi Morita

Förderung

  • Minophagen Pharmaceutical

Zitieren

APA

Sanagawa, A., Hayakawa, T., Nishida, E., Yamamoto, A., Ikumi, K., Mori, Y., Hotta, Y., Kimura, K., Furukawa-Hibi, Y., & Morita, A. (2023). Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16801

Vancouver

Sanagawa A, Hayakawa T, Nishida E, Yamamoto A, Ikumi K, Mori Y, et al. Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16801

BibTeX
@article{Sanagawa2023,
  author = {Sanagawa, Akimasa and Hayakawa, Tomoaki and Nishida, Emi and Yamamoto, Aya and Ikumi, Kyoko and Mori, Yukari and Hotta, Yuji and Kimura, Kazunori and Furukawa-Hibi, Yoko and Morita, Akimichi},
  title = {Impact of body mass index on the severity of bexarotene‐associated hypertriglyceridemia: A post hoc analysis of an open‐labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T‐cell lymphoma},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16801}
}
Kostenlos starten →